Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer
Radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung cancer patients receiving concurrent chemotherapy. Therefore, we investigated the potential of bone marrow sparing with protons for esophageal tumors.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Samantha Warren, Christopher N. Hurt, Thomas Crosby, Mike Partridge, Maria A. Hawkins Tags: Physics Contribution Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Esophagus Cancer | Hematology | Lung Cancer | Physics | Proton Therapy | Radiation Therapy | Radiology | Toxicology